Lacosamide

• Lacosamide is an anticonvulsant indicated for specific seizure types in epilepsy.
• Partial‑onset seizures: reduces the frequency of focal seizures when used as monotherapy or adjunctive therapy.
• Primary generalized tonic‑clonic seizures: used as adjunctive therapy to help control seizure episodes in patients with this seizure type.

• Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes, stabilizing hyperexcitable neuronal membranes and decreasing repetitive neuronal firing, which helps to control seizure activity.

Lacosamide may cause a range of adverse reactions, some of which are common and others that are serious or rare.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Nausea: feeling of stomach upset or urge to vomit.
• Headache: mild to moderate pain in the head region.
• Fatigue: unusual tiredness or lack of energy.
• Blurred vision: temporary visual disturbances.
• Diplopia: double vision.

Serious or Rare Side Effects

• Cardiac arrhythmia: irregular heart rhythm, including PR‑interval prolongation.
• Suicidal ideation: thoughts of self‑harm or suicide.
• Severe skin reactions: such as Stevens‑Johnson syndrome.
• Hepatic injury: signs of liver dysfunction.
• Anaphylaxis: severe allergic reaction with breathing difficulty.
• Cardiac conduction abnormalities: including atrioventricular block.

• When prescribing Lacosamide, clinicians should consider several safety aspects.
• Renal impairment: dose may need adjustment and renal function monitoring.
• Hepatic impairment: monitor liver enzymes and consider dose modification.
• Cardiac conduction: obtain baseline ECG and monitor for PR‑interval changes.
• Concomitant antiepileptics: assess for additive CNS effects and adjust doses.
• Pregnancy and breastfeeding: risk unknown, use only if benefits outweigh risks.
• Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Lacosamide can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce lacosamide levels.
• Other sodium‑channel blockers (e.g., lamotrigine, oxcarbazepine): increase risk of cardiac effects.
• Drugs that prolong PR interval (e.g., diltiazem): may exacerbate conduction delays.

Moderate Interactions (Monitor Closely)

• Oral contraceptives: efficacy may be decreased, consider alternative methods.
• Anticoagulants (e.g., warfarin): monitor INR for potential changes.
• CNS depressants (e.g., alcohol, benzodiazepines): may enhance sedation.
• Antihypertensives: monitor blood pressure for additive effects.
• Other antiepileptics: dose adjustments may be required based on therapeutic response.